Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation and Depletion (2021 - 2025)

Amylyx Pharmaceuticals has reported Depreciation and Depletion over the past 5 years, most recently at $108000.0 for Q4 2025.

  • Quarterly results put Depreciation and Depletion at $108000.0 for Q4 2025, down 32.5% from a year ago — trailing twelve months through Dec 2025 was $525000.0 (down 41.92% YoY), and the annual figure for FY2025 was $525000.0, down 41.92%.
  • Depreciation and Depletion for Q4 2025 was $108000.0 at Amylyx Pharmaceuticals, down from $120000.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for AMLX hit a ceiling of $315000.0 in Q1 2024 and a floor of $10000.0 in Q1 2021.
  • Median Depreciation and Depletion over the past 5 years was $158000.0 (2024), compared with a mean of $152800.0.
  • Biggest five-year swings in Depreciation and Depletion: skyrocketed 1550.0% in 2022 and later plummeted 50.48% in 2025.
  • Amylyx Pharmaceuticals' Depreciation and Depletion stood at $22000.0 in 2021, then soared by 727.27% to $182000.0 in 2022, then soared by 65.38% to $301000.0 in 2023, then crashed by 46.84% to $160000.0 in 2024, then tumbled by 32.5% to $108000.0 in 2025.
  • The last three reported values for Depreciation and Depletion were $108000.0 (Q4 2025), $120000.0 (Q3 2025), and $141000.0 (Q2 2025) per Business Quant data.